Aldeyra Therapeutics/ALDX

$4.25

-3.4%
-
1D1W1MYTD1YMAX

About Aldeyra Therapeutics

Aldeyra Therapeutics, Inc. is a biotechnology company, which is engaged in discovering therapies designed to treat immune-mediated diseases. The Company's product candidates include reactive aldehyde species (RASP) modulators ADX-629, ADX-246, ADX-248, and chemically related molecules for the treatment of systemic and retinal immune-mediated diseases. Its pre-commercial product candidates are reproxalap, a RASP modulator for the potential treatment of dry eye disease and allergic conjunctivitis, and ADX-2191, a novel formulation of intravitreal methotrexate for the treatment of proliferative vitreoretinopathy and retinitis pigmentosa. Its ADX-629, is an orally administered RASP modulator in clinical development for atopic dermatitis, idiopathic nephrotic syndrome, moderate alcohol-associated hepatitis, chronic cough, and Sjogren-Larsson Syndrome. Its preclinical RASP platform includes ADX-246 and ADX-248 in development for metabolic, retinal diseases and systemic inflammatory diseases.

Ticker

ALDX

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Todd Brady

Employees

10

Headquarters

Lexington, United States

ALDX Metrics

BasicAdvanced
$250.31M
Market cap
-
P/E ratio
-$0.64
EPS
1.47
Beta
-
Dividend rate
$250.31M
1.46907
$11.97
$1.42
574.98K
6.64
12.644
-22.78%
-27.73%
-25.71%
2.1
2.089
39.98%

What the Analysts think about ALDX

Analyst Ratings

Majority rating from 8 analysts.
Buy

Price Targets

Average projection from 8 analysts.
117.65% upside
High $11.00
Low $7.00
$4.25
Current price
$9.25
Average price target

ALDX Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$0
-
Net income
$-4.7M
-41.98%
Profit margin
0%
-

ALDX Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 42.96%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$0.27
-$0.15
-$0.14
-$0.08
-
Expected
-$0.29
-$0.31
-$0.24
-$0.14
-$0.11
Surprise
-7.4%
-51.75%
-41.28%
-42.96%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Aldeyra Therapeutics stock?

Aldeyra Therapeutics (ALDX) has a market cap of $250.31M as of April 13, 2024.

What is the P/E ratio for Aldeyra Therapeutics stock?

The price to earnings (P/E) ratio for Aldeyra Therapeutics (ALDX) stock is 0 as of April 13, 2024.

Does Aldeyra Therapeutics stock pay dividends?

No, Aldeyra Therapeutics (ALDX) stock does not pay dividends to its shareholders as of April 13, 2024.

When is the next Aldeyra Therapeutics dividend payment date?

Aldeyra Therapeutics (ALDX) stock does not pay dividends to its shareholders.

What is the beta indicator for Aldeyra Therapeutics?

Aldeyra Therapeutics (ALDX) has a beta rating of 1.47. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

What is the Aldeyra Therapeutics stock price target?

The target price for Aldeyra Therapeutics (ALDX) stock is $9.25, which is 117.65% above the current price of $4.25. This is an average based on projections from 8 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Aldeyra Therapeutics stock

Buy or sell Aldeyra Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing